Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $465,902.56 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 12,368 shares of the business’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $37.67, for a total value of $465,902.56. Following the transaction, the chief operating officer owned 28,684 shares of the company’s stock, valued at $1,080,526.28. The trade was a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Eben Tessari also recently made the following trade(s):

• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $38.33, for a total value of $1,609,860.00.
• On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $36.46, for a total value of $597,944.00.
• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.52, for a total value of $3,028,825.92.
• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.66, for a total value of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.50, for a total value of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.77, for a total value of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80.

Kiniksa Pharmaceuticals International Trading Down 0.7%

Kiniksa Pharmaceuticals International stock opened at $38.64 on Friday. The business has a 50-day moving average of $35.85 and a 200-day moving average of $29.77. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $39.43. The firm has a market capitalization of $2.86 billion, a P/E ratio of 966.24 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently bought and sold shares of KNSA. GAMMA Investing LLC boosted its position in Kiniksa Pharmaceuticals International by 4,003.9% during the 1st quarter. GAMMA Investing LLC now owns 27,496 shares of the company’s stock worth $611,000 after acquiring an additional 26,826 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Kiniksa Pharmaceuticals International by 6.4% during the 1st quarter. Rhumbline Advisers now owns 62,700 shares of the company’s stock worth $1,393,000 after purchasing an additional 3,745 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $301,000. Asset Management One Co. Ltd. bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $41,000. Finally, Wealthquest Corp bought a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $42,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

KNSA has been the subject of several research analyst reports. TD Cowen initiated coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a “buy” rating and a $60.00 price objective for the company. Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Citigroup boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Wedbush upped their price target on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an “outperform” rating in a research report on Monday, October 13th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.